Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Probi AB (publ)
  6. News
  7. Summary
    PROB   SE0001280355


Delayed Quote. Delayed Nasdaq Stockholm - 07/27 11:29:31 am
472 SEK   +0.32%
07/16Probi Seeks Acquisitions
07/16Q2 2021 : Probi enters new strategic partnerships
07/16Probi AB Publ Reports Earnings Results for the Second Quarter Ended June 30, 2021
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Probi : Iron status in healthy pregnant women improved by the probiotic Probi FerroSorb« concept

04/21/2021 | 05:01am EDT

Iron deficiency is the most common micronutrient deficiency and a global health problem. It is a very common challenge for women of childbearing age in general and especially for pregnant women. Therefore, many women start taking food supplements when they become pregnant. However, conventional high dose iron supplements commonly cause side effects like stomach pain and constipation. Thus, a more physiological approach for improving iron status is attractive when developing a new and safe product with clinical evidence.

The previously reported study on improved iron status in healthy pregnant women has now been published: https://obgyn.onlinelibrary.wiley.com/doi/10.1111/aogs.14153.

"The randomized, double-blind, placebo-controlled trial on Probi FerroSorb® included 326 healthy, pregnant women." explains Titti Niskanen, Director R&D & Clinical Operations. Niskanen continues: "Compared to the women in the placebo group, the women taking Probi FerroSorb experienced a significantly lower decrease in serum ferritin, hemoglobin, and other markers of iron status during pregnancy. Moreover, there was a significantly smaller prevalence of iron deficiency and iron deficiency anemia at week 35 in the Probi FerroSorb group vs placebo."

Titti Niskanen adds: "Even eight weeks after giving birth the women who had consumed Probi FerroSorb throughout their pregnancy had a significantly higher ferritin level than women in the placebo group. This improved iron status after delivery may prove beneficial for maternal postpartum recovery as well as for future pregnancies."

Iron absorption and iron status

Iron is absorbed from the diet either as heme iron, derived from animal food sources, or non-heme iron, which is derived from plants and iron-fortified foods. Despite its relative abundance and the relatively low daily iron requirements, iron is often a limiting nutrient in the human diet.

High-dose iron supplements are used to complement an insufficient dietary intake, but a significant part of the iron remains unabsorbed in the intestine, resulting in potential side effects. It has previously been shown that the probiotic strain Lactiplantibacillus plantarum 299v (LP299V®) significantly increases iron absorption from several food matrices.

Iron status is an essential element for the living body. Most of the body's iron is in the haemoglobin of the red blood cells, which carry oxygen to the body. Extra iron can be stored for use when the dietary intake is too low.

"Probi® has previously shown increased iron absorption with Probi FerroSorb in repeated studies, and now we are very proud also being able to show improved iron status. It is a big achievement and a novelty within the probiotic space," says Tom Rönnlund, CEO at Probi.

"This means that this specific ClinBac® offering from Probi is supported by studies on iron absorption in non-pregnant women, and iron status in female athletes and in pregnant women, so it can be recommended to a wide range of consumer groups," Rönnlund continued.

For further information, please contact:

Tom Rönnlund, CEO, Probi®,
Phone: +46 46 286 89 40, E-mail: trd@probi.com

Titti Niskanen, Director R&D & Clinical Operations, Probi®,
Phone: +46 46 286 89 68, E-mail: titti.niskanen@probi.com

Charlotte Beyerholm, Director Marketing & Global Communication, Probi®,
Phone: +46 76 870 94 65, E-mail: charlotte.beyerholm@probi.com



Probi® is a global company focused exclusively on researching, manufacturing, and delivering probiotics for
supplements and functional food. We are experts at managing stable, live bacteria from R&D through every
stage of the manufacturing process and are dedicated to making the health-enhancing benefits of probiotics
available to people everywhere. Our health concepts, formulations, and formats are supported by robust clinical
documentation. Since our founding in 1991 at Sweden's Lund University, Probi has expanded its operations to
more than 40 markets. We hold more than 400 patents globally. Read more at www.probi.com.

Probi® is a registered trademark of Probi AB.




(c) 2021 Cision. All rights reserved., source Press Releases - English

Stocks mentioned in the article
ChangeLast1st jan.
PROBI AB (PUBL) 0.32% 472 Delayed Quote.11.49%
SYMRISE AG 1.28% 123.1 Delayed Quote.13.56%
All news about PROBI AB (PUBL)
07/16Probi Seeks Acquisitions
07/16Q2 2021 : Probi enters new strategic partnerships
07/16Probi AB Publ Reports Earnings Results for the Second Quarter Ended June 30, ..
07/13PROBI : Presentation of Probi's Q2 report 2021
07/13PROBI : Presentation of Probi's Q2 report 2021
07/06PROBI : Snaps Up 13% Stake In Blis Technologies For $6 Million
07/06PROBI : acquires newly issued shares in New Zealand's Blis...
07/06Probi acquires newly issued shares in New Zealand's Blis Technologies and ent..
07/06Blis Technologies and Probi AB Signs a Licensing and Distribution Agreement
06/15PROBI : and Oriflame enter partnership for digestive...
More news
Sales 2021 712 M 82,6 M 82,6 M
Net income 2021 95,0 M 11,0 M 11,0 M
Net cash 2021 251 M 29,1 M 29,1 M
P/E ratio 2021 56,4x
Yield 2021 0,25%
Capitalization 5 378 M 625 M 624 M
EV / Sales 2021 7,20x
EV / Sales 2022 5,97x
Nbr of Employees -
Free-Float 36,6%
Duration : Period :
Probi AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROBI AB (PUBL)
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus -
Number of Analysts 2
Last Close Price 472,00 SEK
Average target price 505,00 SEK
Spread / Average Target 6,99%
EPS Revisions
Managers and Directors
Tom Juhani R÷nnlund Chief Executive Officer
Henrik Lundkvist Chief Financial Officer
Jean-Yves Parisot Chairman
Niklas Brandt Vice President-Information Technology
Niklas Larsson Lead Scientific Affairs
Sector and Competitors
1st jan.Capi. (M$)
PROBI AB (PUBL)11.49%621
NESTLÉ S.A.9.65%343 285
DANONE7.92%44 596